These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Pathogenesis of scleroderma. Current concepts. Lee EB; Anhalt GJ; Voorhees JJ; Diaz LA Int J Dermatol; 1984 Mar; 23(2):85-9. PubMed ID: 6698691 [No Abstract] [Full Text] [Related]
64. What is your diagnosis? Progressive systemic sclerosis (scleroderma). Elston DM Cutis; 2005 Dec; 76(6):357, 385-7. PubMed ID: 16438423 [No Abstract] [Full Text] [Related]
65. Inflammatory morphea in the context of Raynaud phenomenon. Abbasi N; Firoz B; Bossenbroek NM; Meehan SA; Kamino H; Franks AG Dermatol Online J; 2008 Oct; 14(10):11. PubMed ID: 19061610 [TBL] [Abstract][Full Text] [Related]
66. Pathogenesis and treatment modalities of localized scleroderma. Valančienė G; Jasaitienė D; Valiukevičienė S Medicina (Kaunas); 2010; 46(10):649-56. PubMed ID: 21393982 [TBL] [Abstract][Full Text] [Related]
67. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Avouac J; Fransen J; Walker UA; Riccieri V; Smith V; Muller C; Miniati I; Tarner IH; Randone SB; Cutolo M; Allanore Y; Distler O; Valentini G; Czirjak L; Müller-Ladner U; Furst DE; Tyndall A; Matucci-Cerinic M; Ann Rheum Dis; 2011 Mar; 70(3):476-81. PubMed ID: 21081523 [TBL] [Abstract][Full Text] [Related]
68. [Differential diagnosis of scleroderma-like changes in the skin]. Pokorný M Cesk Dermatol; 1973 Oct; 48(5):347-50. PubMed ID: 4762465 [No Abstract] [Full Text] [Related]
69. Scleroderma of the Hand: Evaluation and Treatment. Beldner S; Rabinovich RV; Polatsch DB J Am Acad Orthop Surg; 2020 Aug; 28(16):e686-e695. PubMed ID: 32769717 [TBL] [Abstract][Full Text] [Related]
70. Epidemiology and pathogenesis of scleroderma. Chen K; See A; Shumack S Australas J Dermatol; 2003 Feb; 44(1):1-7; quiz 8-9. PubMed ID: 12581091 [TBL] [Abstract][Full Text] [Related]
71. [Role of esophageal manometry in the diagnosis and developmental control of scleroderma]. Balanzoni S; Bagioni P; Bacchilega R; Catrani S Minerva Dietol Gastroenterol; 1985; 31(2):183-90. PubMed ID: 4034026 [No Abstract] [Full Text] [Related]
72. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis. Yamane K Intern Med; 1994 Oct; 33(10):579-82. PubMed ID: 7827371 [TBL] [Abstract][Full Text] [Related]
74. Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history. Kaushik A; Mahajan R; De D; Handa S Clin Exp Dermatol; 2020 Aug; 45(6):679-684. PubMed ID: 32449205 [TBL] [Abstract][Full Text] [Related]
75. Red flags in scleroderma. Li Q; Sahhar J; Littlejohn G Aust Fam Physician; 2008 Oct; 37(10):831-4. PubMed ID: 19002303 [TBL] [Abstract][Full Text] [Related]
76. [How I explore ... the skin functional involvement in scleroderma]. Hermanns-Lê T; Piérard-Franchimont C; Piérard GE; André B; De Roover C; Renwart L; Delvenne P Rev Med Liege; 2013 Mar; 68(3):141-7. PubMed ID: 23614323 [TBL] [Abstract][Full Text] [Related]
77. [Pathohistological and histochemical changes in the skin of patients with scleroderma during treatment at the Sochi spa]. Al'ter SM Vestn Dermatol Venerol; 1971 Oct; 45(10):40-3. PubMed ID: 5134077 [No Abstract] [Full Text] [Related]
78. Scleroderma. Miller M Aust Fam Physician; 1993 Dec; 22(12):2112-9. PubMed ID: 8304869 [TBL] [Abstract][Full Text] [Related]